FK506 (Tacrolimus, Prograf) is an immunosuppressive drug discovered by Kino et al. in the 1980s1. Since then, it has been used clinically for an increasing number of immunological disorders. FK506 exerts its therapeutic effects by suppression of T-cell activation, without markedly affecting bone...
PubMedCASGoogle Scholar Fung J. J., Eliasziw M., Todo S., Jain A., Demetris A. J., McMichael J. P., Starzl T. E., Meier P., and Donner A. (1996) The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.J. Am. Coll. Surg.183, 117–125...
Crystal structures of CN–FK506-FKBP12 ternary complexes from four fungi were determined by molecular replacement to resolutions between 1.85 and 3.30 Å (Table1). Each complex has three components: (1) the CnA subunit with catalytic domain and the BBH, (2) the CnB subunit, with four ...
Keywords: Streptomyces tsukubaensis, FK506, Genome-scale metabolic model, Target prediction, Metabolic engineering, Combinatorial modification Background FK506 (tacrolimus), which is produced by Streptomyces tsukubaensis, is a 23-membered polyketide macrolide (Figure 1A). It has been used as an ...